Navigation Links
Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Date:1/7/2011

RESEARCH TRIANGLE PARK, N.C., Jan. 7, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.

Under the expanded-access protocol developed in conjunction with the U.S. Food and Drug Administration (FDA), patients will receive treatment with CMX001 for any of 12 different dsDNA viral infections, including adenovirus (AdV), herpes viruses (cytomegalovirus (CMV), herpes simplex virus (HSV) and Epstein Barr virus), polyoma viruses (BK virus and JC virus), and pox viruses.  The CMX001-350 study will enroll 200 patients at major medical centers primarily in the United States.

CMX001 is being developed by Chimerix for dual-use as a broad-spectrum antiviral for the treatment of life-threatening viral infections in immunocompromised patients and as a medical countermeasure in the event of a smallpox outbreak.  Chimerix is currently conducting a Phase 2 dose-defining clinical study of CMX001 in immunocompromised hematopoietic stem cell transplant patients at risk of life-threatening infection with CMV, which has enrolled over 130 patients. Additionally, the Company is initiating a Phase 2 clinical study in immunocompromised pediatric and adult hematopoietic stem cell transplant patients with AdV infections.

"Data from this open-label clinical study will be a critical component of our strategy to develop CMX001 as a broad-spectrum antiviral agent," said Kenneth I. Moch, President and CEO of Chimerix.  "We anticipate that the CMX001-350 study will provide important supportive data for our overall clinical development program."

"CMX001 is exhibiting a favorable tolerability profile and signs of potent antiviral activity across our clinical studie
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Research and Markets  has ... Pralmorelin" report to their offering. Global ... data on Pralmorelin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Corp., formerly known as InstaCare Corp., (OTCQB: ISCRD), a ... the chronically ill, a leading fulfillment provider of direct ... revolutionary cell phone centric e -health products and ... Dividend will be Ex-Dividend to all shareholders of record ...
... ENDP ) today announced that David Holveck, president ... Morgan 30th Annual Healthcare Conference on Monday, January 9, 2012 ... the Westin St. Francis in San Francisco, Calif. ... be available on the company,s website at http://www.endo.com/ .  ...
Cached Medicine Technology:Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy 2
(Date:8/21/2014)... HIPAA Secure Now! rolled out its EHR (electronic ... vendors to now offer their customers a HIPAA security ... , HIPAA Secure Now! provides risk analysis services, ... U.S. The company assesses the risks of storing and ... and device used by the practice. , HIPAA ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... August 21, 2014 The rising numbers of ... Boynton Beach, FL. For many years, countless lives have been ... in the community a new helpline was established to provide ... Florida who are seeking to overcome their youth substance ... Boynton Beach helpline at (561) 257-4053, parents and their teens ...
(Date:8/21/2014)... August 21, 2014 Drake University’s Phi ... $10,000 to support ovarian cancer research, according to Billy ... is also the kicker for the Cleveland Browns, says ... was matched by Colleen’s Dream Foundation and will fund ... Assistant Professor in the Division of Gynecologic Oncology at ...
(Date:8/20/2014)... August 21, 2014 Top 10 ... web hosting companies and announced Bluehost ( http://www.bluehost.com/track/seohosts ... hosting companies that provide high quality PHP hosting ... Top 10 Best SEO Hosting are unbiased and ... the best information possible. During the recent years, ...
Breaking Medicine News(10 mins):Health News:HIPAA Secure Now! Ramps up EHR Partner Program, Helps Healthcare Providers Achieve Meaningful Use under Revised CMS Deadlines 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Troubled Teens in Boynton Beach, FL Turn to Helpline for Valuable Assistance 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3Health News:New Reviews Of Cheap PHP Hosting Companies Unveiled By Top 10 Best SEO Hosting 2
... Bethesda, MD (November 1, 2007) Diabetes is a very ... the U.S. and it is estimated an additional 54 million ... blood glucose levels are higher than normal but not high ... is important to determine whether glucose and insulin levels are ...
... Nov. 1 NuVasive, Inc. (Nasdaq:,NUVA), a medical device ... for the spine, announced today,that Alex Lukianov, Chairman and ... Investor Conference 2007 at the San Diego Marriott,Del Mar ... 2007 at 9:30 a.m.,PT. A live Web cast ...
... See their First Birthday, LOS ANGELES, Nov. 1 On ... all babies -- those born healthy,those who need help to thrive ... infants die before their first birthday each year -- more,than 5,000 ... Vicente Perez, Jr. is just one of those., He was ...
... Reps. Shelley Moore Capito and Tom Allen Express ... Nov. 1 Warning that cuts to,seniors, Medicare ... quality of,care and quality of life of America,s ... care, a broad array of clinician and,caregiver groups ...
... Mayo Clinic study of a drug that has shown promise ... drug may also be effective in treating breast cancer, in ... was done in mouse models, is featured on the cover ... National Cancer Institute reports that of 240,510 breast cancer diagnoses ...
... slowly to save their lives can be an invasive ... to the November issue of Journal of Clinical Nursing. ... Dublin, has called for clinical and legal guidelines to ... and highlighted the need for better communication about do ...
Cached Medicine News:Health News:Increased glucose level is a strong risk factor for colorectal cancer 2Health News:Increased glucose level is a strong risk factor for colorectal cancer 3Health News:NuVasive to Present at BIOCOM Investor Conference 2007 2Health News:NuVasive to Present at BIOCOM Investor Conference 2007 3Health News:March of Dimes Honors Babies on 'El Dia de Todos los Santos' 2Health News:Coalition of Caregivers Warns Congress of Danger to Oldest U.S. Seniors if Medicare Slashed 2Health News:Coalition of Caregivers Warns Congress of Danger to Oldest U.S. Seniors if Medicare Slashed 3Health News:Coalition of Caregivers Warns Congress of Danger to Oldest U.S. Seniors if Medicare Slashed 4Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 2Health News:Mayo Clinic study shows drug could effectively treat, prevent the spread of breast cancer 3Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 2Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 3
The Sutura family of products is designed to allow interventionalists to perform vessel closure from 6F up to 24F. It's elegant design allows one-handed use through sheath, routinely eliminating need...
The Closer vascular closure device is a suture mediated closure system. It has a sheath-like profile and easy positioning. It has an innovative design which involves the needles outside the artery an...
Spyglass angiography catheters, combined with St. Jude Medical hemostasis introducers and GuideRight guidewires, offer a safe and effective diagnostic angiography system....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Medicine Products: